Zacks Investment Research downgraded shares of Check Cap (NASDAQ:CHEK) from a buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

CHEK has been the subject of several other reports. Dougherty & Co initiated coverage on Check Cap in a report on Tuesday, February 5th. They set a buy rating and a $6.00 price target for the company. HC Wainwright set a $14.00 price target on Check Cap and gave the stock a buy rating in a report on Friday, December 14th.

NASDAQ:CHEK opened at $2.70 on Tuesday. The company has a market cap of $4.32 million and a P/E ratio of -1.03. Check Cap has a 1-year low of $1.62 and a 1-year high of $19.78.

Check Cap (NASDAQ:CHEK) last released its quarterly earnings results on Thursday, March 28th. The medical research company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.04). Analysts predict that Check Cap will post -1.7 earnings per share for the current year.

A hedge fund recently bought a new stake in Check Cap stock. Dimensional Fund Advisors LP purchased a new position in shares of Check Cap Ltd (NASDAQ:CHEK) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 35,131 shares of the medical research company’s stock, valued at approximately $141,000. Dimensional Fund Advisors LP owned about 2.20% of Check Cap at the end of the most recent quarter.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Recommended Story: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.